Definitive Contract 75N93024C00029
Award Date
8/1/24
Potential Completion Date
4/14/25
Potential Value
$299K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Darwin Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boulder, CO 80301, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Accelevir Diagnostics LLC, a woman-owned small business. The contract, valued at $299,975.00, is for the company to adapt its Intact Proviral DNA Assay (IPDA) to measure latent HIV-1 for individuals with the CRF-1_AE genetic subtype of the virus. This contract is part of NIAID's Small Business Innovation Research (SBIR)...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Vitruvian Bio, LLC, a small disadvantaged and woman-owned business. The $299,968 firm fixed-price contract is for the development of an electrochemical self-monitoring device for rapid nucleic acid-based testing of HIV-1. This award is focused on advancing innovative point-of-care diagnostic...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virodx LLC, a minority-owned, woman-owned small business. The contract is for the development of a "METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV" and has a firm fixed price of $112,496.00 with a completion date of June 29, 2017. As this is an SBIR Phase I contract, the focus is on research...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,206.00 firm fixed-price Small Business Innovation Research (SBIR) Phase I contract to Intuitive Biosciences Inc., a small disadvantaged business, to develop "THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES." This contract is linked to a broader SBIR solicitation issued by the NIAID and Centers for Disease Control...
The Department of Health and Human Services, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Fluid Discovery, Inc., a for-profit small business, to develop "Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis." The $299,903 firm-fixed-price contract, which runs through July 31, 2024, supports research and development of innovative...
<p>The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Aldatu Biosciences, Inc. for the development of a rapid, sensitive, and cost-effective method to detect drug-resistant HIV minority variants. The contract, valued at $298,690.00, is a Definitive Contract with a Firm Fixed Price pricing type. The contract has an ultimate completion date of December 14, 2017.</p>
This is a $299,986 firm fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Big Eye Diagnostics Inc., a small business manufacturer, for the development and validation of novel diagnostic biomarkers for malaria and select neglected tropical diseases. The contract is part of NIAID's Small Business Innovation Research (SBIR) program, which provides funding to small businesses for innovative research and development. The objective is to create rapid,...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS). The $128,312.76 cost-plus-fixed-fee contract was awarded to Southern Research Institute, a non-profit organization that provides research and development services, to develop new assays for HIV therapeutics and topical microbicides. The contract does not have a set-aside designation. Southern Research Institute...
This is a $403,478.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Southern Research Institute, a non-profit research organization. The contract is for conducting hit-to-lead progression studies on investigational agents for the treatment of HIV. This work will be performed under NIAID's Preclinical Services for HIV Therapeutics indefinite...